公开(公告)号：US20150266824A1

公开(公告)日：2015-09-24

申请号：US14633936

申请日：2015-02-27

Applicant: AMGEN INC. ,  Teijin Pharma Limited

Inventor： Hilary Plake Beck ,  Shon Keith Booker ,  Howard Bregman ,  Victor J. Cee ,  Nagasree Chakka ,  Timothy D. Cushing ,  Oleg Epstein ,  Brian M. Fox ,  Stephanie Geuns-Meyer ,  Xiaolin Hao ,  Kenta Hibiya ,  Jun Kirata ,  Zihao Hua ,  Jason Human ,  Shinji Kakuda ,  Patricia Lopez ,  Ryota Nakajima ,  Kazuhisa Okada ,  Steven H. Olson ,  Hiroyuki Oono ,  Lewis D. Pennington ,  Kosuke Sasaki ,  Keiko Shimada ,  Youngsook Shin ,  Ryan D. White ,  Ryan P. Wurz ,  Shuyan Yi ,  Xiao Mei Zheng

IPC: C07D231/14 ,  C07D409/12 ,  C07D413/12 ,  C07D405/14 ,  C07D401/14 ,  C07D493/08 ,  C07D401/12 ,  C07D403/12

CPC classification number: C07D231/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/14 ,  C07D493/08

Abstract: The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

Abstract translation: 本发明涉及具有抑制RORγ活性的新型化合物。 本发明还涉及包含该化合物的药物组合物，该化合物在治疗或预防自身免疫疾病，炎性疾病，代谢疾病或癌症疾病中的用途。

公开(公告)号：US09873701B2

公开(公告)日：2018-01-23

申请号：US14520899

申请日：2014-10-22

Applicant: AMGEN INC.

Inventor： Yi Chen ,  Timothy D. Cushing ,  Jason A. Duquette ,  Felix Gonzalez Lopez De Turiso ,  Xiaolin Hao ,  Xiao He ,  Brian S. Lucas ,  Lawrence R. McGee ,  Andreas Reichelt ,  Robert M. Rzasa ,  Jennifer L. Seganish ,  Youngsook Shin ,  Dawei Zhang

IPC: C07D487/04 ,  C07D473/30 ,  C07D473/34 ,  C07D471/04

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D473/30 ,  C07D473/34

Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

公开(公告)号：US09365522B2

公开(公告)日：2016-06-14

申请号：US14633936

申请日：2015-02-27

Applicant: AMGEN INC. ,  TEIJIN PHARMA LIMITED

Inventor： Hilary Plake Beck ,  Shon Keith Booker ,  Howard Bregman ,  Victor J. Cee ,  Nagasree Chakka ,  Timothy D. Cushing ,  Oleg Epstein ,  Brian M. Fox ,  Stephanie Geuns-Meyer ,  Xiaolin Hao ,  Kenta Hibiya ,  Jun Hirata ,  Zihao Hua ,  Jason Human ,  Shinji Kakuda ,  Patricia Lopez ,  Ryota Nakajima ,  Kazuhisa Okada ,  Steven H. Olson ,  Hiroyuki Oono ,  Lewis D. Pennington ,  Kosuke Sasaki ,  Keiko Shimada ,  Youngsook Shin ,  Ryan D. White ,  Ryan P. Wurz ,  Shuyan Yi ,  Xiao Mei Zheng

IPC: C07D231/14 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/14 ,  C07D493/08 ,  C07D413/12 ,  A61K31/4155 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/422

CPC classification number: C07D231/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/14 ,  C07D493/08

Abstract: The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

Abstract translation: 本发明涉及具有抑制RORγ活性的新型化合物。 本发明还涉及包含该化合物的药物组合物，该化合物在治疗或预防自身免疫疾病，炎性疾病，代谢疾病或癌症疾病中的用途。